Max Gelman – Endpoints News

SIGN UP

about the author

Max Gelman

Senior Editor

max@endpointsnews.com @MaxGelman

Max Gelman on LinkedIn

Max Gelman writes about the big-picture ideas and trends that drive the biopharma world, with particular interests in immunology and neuroscience. A graduate of Northwestern University, Max joined Endpoints in July 2020 after a few stints covering baseball and college sports. He currently lives in New York City.

author articles

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

14 hours ago

Taking advantage of recent successes, Roche will push obesity drugs faster, flirts with M&A

Yesterday

BioNTech signs 3D printing deal to develop oral RNA drugs

2 days ago

With new mission in psychiatry, Autobahn raises $100M to help back Phase 2 work

2 days ago

Neurology startup from OrbiMed collab nabs $65M in Series A

3 days ago

HI-Bio dishes on motivations for Biogen buyout, citing desire to move fast

4 days ago

Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

4 days ago

4DMT builds out case for wet AMD gene therapy with new Phase 2 data

Last week

Adverum prepares pivotal study for wet AMD gene therapy, touts Phase 2 data

Last week

FDA again rejects Orexo's nasal spray for opioid overdose rescue

Last week

Ideaya raises $302M; AbbVie to seek approval in giant cell arteritis

2 weeks ago

UniQure trumpets mid-stage data for Huntington's disease gene therapy

3 weeks ago

Following a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot

4 weeks ago

Alnylam's big Phase 3 win; LGBTQ+ leaders charting paths; Chevron overturned; and more

4 weeks ago

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

5 weeks ago

Silence reports Phase 1 data from rare blood disorder trial

5 weeks ago

Wave Life Sciences touts Huntington's disease win in Phase 1b/2a trial

Last month

FDA again rejects AbbVie's continuous infusion therapy for Parkinson's

Last month

Lexicon resubmits type 1 diabetes drug to FDA five years after rejection

Last month

PTC touts Phase 2 biomarker data for Huntington’s drug, showing dose-dependent effect at one year

Last month

AbbVie adds ulcerative colitis to Skyrizi label

Last month

Updated: FDA places partial hold on BioNTech-MediLink ADC after multiple deaths

Last month

Ultragenyx to seek accelerated approval for rare disease gene therapy

Last month

AbbVie banks on second-gen TL1A program, licensing antibody from FutureGen

Last month

12 3 4 Next page Last page